Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China

Reuters

2025/09/05

Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China

Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology $(CSCO)$ Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable $(MSS)$ colorectal cancer $(CRC)$. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2565656652"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565656652\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565656652?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565656652","market":"nz","top_or_hot":-1,"title":"Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology <a href=\"https://laohu8.com/S/CSCO\">$(CSCO)$</a> Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a>. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-05 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology <a href=\"https://laohu8.com/S/CSCO\">$(CSCO)$</a> Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a>. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDLbxCv5:1","article_id":"2565656652","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565656652","pubTimestamp":1757080526,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire  on September 05, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","ADAG":"天演药业"},"translate_title":"Adagene Inc.在2025年中国CSCO会议上宣布ADG126与帕博利珠单抗联合用药的良好结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ADAG":0.9},"content_text":"Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n    \n\n        Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology $(CSCO)$ Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable $(MSS)$ colorectal cancer $(CRC)$. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}